
Opinion|Videos|October 9, 2025
Video: Exploring the Role of IL-13 Inhibition in AD: Clinical Perspectives & Practical Applications
A pair of leading subject matter experts discuss the current landscape of atopic dermatitis, including unmet needs, and the role of IL-13 inhibition in the management.
Advertisement
Advertisement
Related to this article

Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.

Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.

Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Stepwise Chronic Spontaneous Urticaria Management, With Timothy Craig, DO
2
Asundexian’s FDA Approval Opens Doors for Future Antithrombotic Therapies
3
Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma
4
Upadacitinib Response Within Days in Crohn’s Disease, With Raja Atreya, MD
5


